Literature DB >> 20351350

Impact of dynamic 18F-FDG PET on the early prediction of therapy outcome in patients with high-risk soft-tissue sarcomas after neoadjuvant chemotherapy: a feasibility study.

Antonia Dimitrakopoulou-Strauss1, Ludwig G Strauss, Gerlinde Egerer, Julie Vasamiliette, Gunhild Mechtersheimer, Thomas Schmitt, Burkhard Lehner, Uwe Haberkorn, Philipp Stroebel, Bernd Kasper.   

Abstract

UNLABELLED: Dynamic PET (dPET) studies with (18)F-FDG were performed in patients with soft-tissue sarcomas who received neoadjuvant chemotherapy early in the course of therapy. The goal of the study was to evaluate the impact of early dPET studies and assess their value with regard to the therapy outcome using histopathologic data.
METHODS: The evaluation included 31 patients with nonmetastatic soft-tissue sarcomas, who were treated with neoadjuvant chemotherapy consisting of etoposide, ifosfamide, and doxorubicin. Patients were examined before the onset of therapy and after the completion of the second cycle. Histopathologic response served for reference and was available for 25 of 31 patients. Response was defined as less than 10% viable tumor tissue in the resected tumor tissue. The following parameters were retrieved from dPET studies: standardized uptake value (SUV); fractal dimension; 2-compartment model with computation of K(1), k(2), k(3), and k(4) (unit, 1/min); fractional blood volume; and influx according to Patlak.
RESULTS: The mean SUV was 4.6 before therapy and 2.8 after 2 cycles. The mean influx was 0.059 before therapy and 0.043 after 2 cycles. The mean SUV was 3.9 in the responders and 5.5 in the nonresponders before therapy. After therapy, responders revealed a mean SUV of 2.5, whereas nonresponders had a mean SUV of 3.5. We used linear discriminant analysis to categorize the patients into 2 groups: response (n = 12) and nonresponse (n = 13). The correct classification rate of the responders (positive predictive value) was generally higher (>67%) than that for the nonresponders. Finally, the combined use of the 2 predictor variables, namely SUV and influx, of each study led to the highest accuracy of 83%. This combination was particularly useful for the prediction of responders (positive predictive value, 92%). The use of the percentage change in maximum SUV led to an accuracy of 58%.
CONCLUSION: On the basis of these results, only a multiparameter analysis based on kinetic (18)F-FDG data of a baseline study and after 2 cycles is helpful for the early prediction of chemosensitivity in patients with soft-tissue sarcomas receiving neoadjuvant chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20351350     DOI: 10.2967/jnumed.109.070862

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  18 in total

Review 1.  [Current state of neoadjuvant therapy of soft tissue sarcoma].

Authors:  M Lehnhardt; T Schmitt; M Bischof; A Daigeler; G Egerer
Journal:  Chirurg       Date:  2011-11       Impact factor: 0.955

Review 2.  Importance of quantification for the analysis of PET data in oncology: review of current methods and trends for the future.

Authors:  Giampaolo Tomasi; Federico Turkheimer; Eric Aboagye
Journal:  Mol Imaging Biol       Date:  2012-04       Impact factor: 3.488

3.  Real-time FDG PET guidance during biopsies and radiofrequency ablation using multimodality fusion with electromagnetic navigation.

Authors:  Aradhana M Venkatesan; Samuel Kadoury; Nadine Abi-Jaoudeh; Elliot B Levy; Roberto Maass-Moreno; Jochen Krücker; Sandeep Dalal; Sheng Xu; Neil Glossop; Bradford J Wood
Journal:  Radiology       Date:  2011-07-06       Impact factor: 11.105

4.  Evaluation of the Genisys4, a bench-top preclinical PET scanner.

Authors:  Ken Herrmann; Magnus Dahlbom; David Nathanson; Liu Wei; Caius Radu; Arion Chatziioannou; Johannes Czernin
Journal:  J Nucl Med       Date:  2013-04-29       Impact factor: 10.057

5.  18F-FDG-PET/CT Imaging as an early survival predictor in patients with primary high-grade soft tissue sarcomas undergoing neoadjuvant therapy.

Authors:  Ken Herrmann; Matthias R Benz; Johannes Czernin; Martin S Allen-Auerbach; William D Tap; Sarah M Dry; Tibor Schuster; Jeff J Eckardt; Michael E Phelps; Wolfgang A Weber; Fritz C Eilber
Journal:  Clin Cancer Res       Date:  2012-02-14       Impact factor: 12.531

6.  Positron emission tomography in patients with aggressive fibromatosis/desmoid tumours undergoing therapy with imatinib.

Authors:  Bernd Kasper; Antonia Dimitrakopoulou-Strauss; Ludwig G Strauss; Peter Hohenberger
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-06-19       Impact factor: 9.236

7.  Sarcoma mid-therapy [F-18]fluorodeoxyglucose positron emission tomography (FDG PET) and patient outcome.

Authors:  Janet F Eary; Ernest U Conrad; Janet O'Sullivan; Douglas S Hawkins; Scott M Schuetze; Finbarr O'Sullivan
Journal:  J Bone Joint Surg Am       Date:  2014-01-15       Impact factor: 5.284

8.  Evaluation of chemotherapy response with serum squamous cell carcinoma antigen level in cervical cancer patients: a prospective cohort study.

Authors:  Mingzhu Yin; Yan Hou; Tao Zhang; Changyi Cui; Xiaohua Zhou; Fengyu Sun; Huiyan Li; Xia Li; Jian Zheng; Xiuwei Chen; Cong Li; Xiaoming Ning; Kang Li; Ge Lou
Journal:  PLoS One       Date:  2013-01-22       Impact factor: 3.240

9.  The Potential Benefit by Application of Kinetic Analysis of PET in the Clinical Oncology.

Authors:  Mustafa Takesh
Journal:  ISRN Oncol       Date:  2012-12-26

10.  Positron emission tomography as a surrogate marker for evaluation of treatment response in patients with desmoid tumors under therapy with imatinib.

Authors:  Bernd Kasper; Antonia Dimitrakopoulou-Strauss; Lothar R Pilz; Ludwig G Strauss; Christos Sachpekidis; Peter Hohenberger
Journal:  Biomed Res Int       Date:  2013-05-16       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.